N
Noémie Kraaijpoel
Researcher at University of Amsterdam
Publications - 46
Citations - 1206
Noémie Kraaijpoel is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 14, co-authored 38 publications receiving 735 citations. Previous affiliations of Noémie Kraaijpoel include Public Health Research Institute.
Papers
More filters
Journal ArticleDOI
Venous Thromboembolism: Advances in Diagnosis and Treatment
Tobias Tritschler,Noémie Kraaijpoel,Grégoire Le Gal,Grégoire Le Gal,Philip S. Wells,Philip S. Wells +5 more
TL;DR: Over the past 5 years, substantial progress has been made in VTE management, allowing for diagnostic and therapeutic strategies tailored to individual patient characteristics, preferences, and values.
Journal ArticleDOI
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
Ingrid Pabinger,Nick van Es,Georg Heinze,Florian Posch,Florian Posch,Julia Riedl,Eva-Maria Reitter,Marcello Di Nisio,Gabriela Cesarman-Maus,Noémie Kraaijpoel,Christoph C. Zielinski,Harry R. Büller,Cihan Ay +12 more
TL;DR: An externally validated clinical prediction model incorporating only one clinical factor and one biomarker predicted the risk of venous thromboembolism in ambulatory patients with solid cancers, and could aid physicians in selection of patients who will likely benefit from thromboprophylaxis.
Journal ArticleDOI
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Noémie Kraaijpoel,Marcello Di Nisio,Frits I. Mulder,Nick van Es,Jan Beyer-Westendorf,Marc Carrier,David A. Garcia,Michael A. Grosso,Ajay K. Kakkar,Michele Mercuri,Saskia Middeldorp,Cristhiam Rojas Hernandez,Amparo Santamaría,Lee Schwocho,Annelise Segers,Peter Verhamme,Tzu-Fei Wang,Jeffrey I. Weitz,George Zhang,Jeffrey I. Zwicker,Harry R. Büller,Gary E. Raskob +21 more
TL;DR: It is suggested that while oral edoxaban is an appropriate alternative to subcutaneous dalteparin for treatment of cancer-associated VTE, the use of Edoxaban in patients with gastrointestinal cancer requires careful benefit-risk weighting.
Journal ArticleDOI
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study
Noémie Kraaijpoel,Suzanne M. Bleker,Guy Meyer,Isabelle Mahé,Andrés Muñoz,Laurent Bertoletti,Annemarieke Bartels-Rutten,Jan Beyer-Westendorf,Ettore Porreca,Carine Boulon,Nick van Es,Diana I Iosub,Francis Couturaud,M. Biosca,Teresa Lerede,Philippe Lacroix,Anthony Maraveyas,Anita Aggarwal,Philippe Girard,Harry R. Büller,Marcello Di Nisio,Upe investigators +21 more
TL;DR: In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment despite treatment with low-molecular-weight heparin.
Journal ArticleDOI
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Frits I. Mulder,N. van Es,Noémie Kraaijpoel,M. Di Nisio,Marc Carrier,Anil Duggal,Manila Gaddh,David A. Garcia,Michael A. Grosso,Ajay K. Kakkar,Michele Mercuri,Saskia Middeldorp,Gordon Royle,Annelise Segers,Sudeep Shivakumar,Peter Verhamme,Tzu-Fei Wang,J. I. Weitz,George Zhang,H. R. Büller,Gary E. Raskob +20 more
TL;DR: Edoxaban has a similar risk-benefit ratio to dalteparin in most cancer groups, and in those with gastrointestinal cancer, the lower risk of recurrent VTE and the advantages of oral therapy need to be balanced against the increased risk of major bleeding.